People living with dementia will help close a long-standing weakness in research - the clinical trial evidence gap - in a new home-based study. While those over 65 account for two-thirds of illness in the UK, they make up just one-third of trial participants. This...
In its most significant structural overhaul since the 2021 Organon spin-off, MSD (known as Merck & Co. in the U.S. and Canada) has announced the division of its Human Health business into two standalone units: an Oncology Business Unit and a Specialty, Pharma...
A New Era for EHR Data A new study published in the latest issue of the Royal College of Physicians’ Future Healthcare Journal introduces PICTURE, an innovative data platform designed to convert routine electronic health record (EHR) data into actionable clinical...
After the success of previous summits, the revolutionary Smart Ageing Summit has announced a return to Oxford this May to host its fourth annual event. Rhodes House, University of Oxford is the perfect setting for non-profit organisation Oxford Health Project to host...
British research expertise to deliver faster cancer diagnosis and cleaner energy Major new backing for medical imaging centres across the UK alongside tidal energy testing expansion in Orkney and cutting-edge materials. From: Department for Science, Innovation and...
The global market for GLP-1 receptor agonists, once defined by scarcity and premium pricing, is entering a new phase. Prices for these blockbuster medicines, used to treat obesity and type 2 diabetes, are beginning to fall rapidly, forcing pharmaceutical companies,...
The life science sector encompassing pharmaceuticals, biotechnology, medical technologies, diagnostics and related services is evolving rapidly. Success in this industry no longer rests solely on scientific discovery. Increasingly it depends on the right talent,...
A landmark milestone in global health has been reached as the antimalarial drug Coartem Baby has received approval from the Swiss regulator Swissmedic. It is the first treatment specifically designed for newborns and very young infants suffering from malaria. Bridging...
Danish pharmaceutical leader Novo Nordisk has made a dramatic late entry into the takeover race for United States biotech Metsera, challenging Pfizer’s earlier agreement and sparking a fierce bidding war in one of the most competitive areas of the life sciences...
London, Oxford and Cambridge have long been the heartlands of the UK life sciences sector, but other regions across the country are now rapidly emerging as centres of innovation. The Midlands, the North of England, Scotland and Northern Ireland are developing strong...
The Crown Estate has completed the acquisition of Harwell East, a 221 acre site adjacent to the Harwell Science and Innovation Campus in Oxfordshire. The development could deliver up to 4.5 million square feet of laboratory, research, manufacturing and office space,...
A new multi cancer blood test developed by the United States biotechnology company Grail has demonstrated in North America the ability to detect a wide range of cancers, including many for which no screening programmes exist, at an early and potentially treatable...
Amazon is gearing up to roll out prescription kiosks inside One Medical clinics in Los Angeles beginning December 2025. These in office machines will allow patients to collect common prescription medications such as antibiotics, inhalers, and treatments for high blood...
Eli Lilly & Company is doubling down on U.S. investment, unveiling a series of ambitious plans to expand its domestic pharmaceutical manufacturing infrastructure. These efforts come amid mounting political pressure to reshore drug production and rising competition...
In late September 2025, former U.S. President Donald J. Trump revived a series of controversial health claims and policy proposals concerning women especially pregnant women and children, triggering sharp pushback from medical experts, public health authorities, and...
The NHS in England is leading the world as the first healthcare system to introduce a pioneering ‘trojan horse’ therapy for patients with blood cancer, offering the potential to delay disease progression nearly three times longer than current treatment options....